Australia's Therapeutic Goods Administration has approved clinical trials for a blood test designed to detect Alzheimer's disease biomarkers [1].
This development matters because it could replace expensive and invasive diagnostic tools. Current methods for identifying the disease typically require PET scans or lumbar punctures, which are often costly and difficult for patients to access [1, 3].
The TGA granted the approval in partnership with a coalition of clinicians, researchers, government agencies, and industry partners [1]. The clinical trials are expected to take place at a new Alzheimer's diagnosis centre located in Sydney [1].
Early detection is the primary goal of the trial. Reports said the blood test could identify signs of Alzheimer's disease up to 20 years earlier than current methods [2]. Other data suggests the test could identify risk up to 10 years before symptoms start [3].
By identifying the disease in its earliest stages, medical professionals hope to implement interventions before significant cognitive decline occurs. The blood-based approach offers a more accessible alternative for screening larger populations, a shift that could change how the disease is managed on a public health scale [1, 3].
Trials are expected to begin within months of the approval [1, 2].
“The blood test could identify signs of Alzheimer's disease up to 20 years earlier than current methods.”
The shift toward blood-based biomarkers represents a potential pivot in neurology from reactive diagnosis to proactive screening. If the trials prove successful, the ability to detect Alzheimer's a decade or more before symptom onset could accelerate the development of preventative therapies and allow patients to plan for long-term care significantly earlier.
